Long‐term outcomes for most PTCL subtypes are poor; the 5‐year overall survival (OS) rate was reported at 70% for anaplastic lymphoma kinase (ALK)+ ALCL and <50% for other major subtypes 4, 5. This evidence concerns the gene ALK and anaplastic large cell lymphoma.